Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1957 3
1958 2
1959 1
1961 4
1962 4
1963 5
1964 6
1965 9
1966 4
1967 4
1968 8
1969 7
1970 9
1971 9
1972 11
1973 7
1974 12
1975 8
1976 6
1977 9
1978 18
1979 15
1980 20
1981 22
1982 21
1983 23
1984 28
1985 30
1986 42
1987 42
1988 42
1989 41
1990 46
1991 43
1992 53
1993 40
1994 39
1995 59
1996 64
1997 64
1998 65
1999 72
2000 82
2001 110
2002 81
2003 83
2004 88
2005 98
2006 114
2007 92
2008 119
2009 105
2010 121
2011 137
2012 152
2013 148
2014 193
2015 208
2016 213
2017 191
2018 184
2019 147
2020 196
2021 222
2022 199
2023 205
2024 228
2025 212
2026 76

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,532 results

Results by year

Filters applied: . Clear all
Page 1
Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.
Nakazawa Y, Miyano M, Tsukamoto S, Kogai H, Yamamoto A, Iso K, Inoue S, Yamane Y, Yabe Y, Umihara H, Taguchi J, Akagi T, Yamaguchi A, Koga M, Toshimitsu K, Hirayama T, Mukai Y, Machinaga A. Nakazawa Y, et al. Among authors: yamamoto a. Nat Commun. 2024 Mar 11;15(1):2192. doi: 10.1038/s41467-024-46167-1. Nat Commun. 2024. PMID: 38467634 Free PMC article.
Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease.
Kambara Y, Fujiwara H, Yamamoto A, Gotoh K, Tsuji S, Kunihiro M, Oyama T, Terao T, Sato A, Tanaka T, Peltier D, Seike K, Nishimori H, Asada N, Ennishi D, Fujii K, Fujii N, Matsuoka KI, Soga Y, Reddy P, Maeda Y. Kambara Y, et al. Among authors: yamamoto a. Blood. 2025 Feb 20;145(8):881-896. doi: 10.1182/blood.2024024540. Blood. 2025. PMID: 39693612 Free PMC article.
A rare genetic variant confers resistance to neurodegeneration across multiple neurological disorders by augmenting selective autophagy.
Croce KR, Ng C, Pankiv S, Albarran E, Langfelder P, Ramos de Jesus A, Duncan GM, Wang N, Basile A, McHugh C, Litt NA, Li A, Friedman S, Cortes EP, Zody MC, Yang XW, Ding JB, Vonsattel JPG, Simonsen A, Housman DE, Wexler NS, Yamamoto A. Croce KR, et al. Among authors: yamamoto a. Neuron. 2025 Nov 19;113(22):3780-3797.e7. doi: 10.1016/j.neuron.2025.08.018. Epub 2025 Sep 12. Neuron. 2025. PMID: 40945514 Free PMC article.
PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer.
Yamamoto T, Hayashida T, Masugi Y, Oshikawa K, Hayakawa N, Itoh M, Nishime C, Suzuki M, Nagayama A, Kawai Y, Hishiki T, Matsuura T, Naito Y, Kubo A, Yamamoto A, Yoshioka Y, Kurahori T, Nagasaka M, Takizawa M, Takano N, Kawakami K, Sakamoto M, Wakui M, Yamamoto T, Kitagawa Y, Kabe Y, Horisawa K, Suzuki A, Matsumoto M, Suematsu M. Yamamoto T, et al. Among authors: yamamoto a. Cancer Res. 2024 Apr 1;84(7):1065-1083. doi: 10.1158/0008-5472.CAN-23-2266. Cancer Res. 2024. PMID: 38383964 Free PMC article.
Macrophage WDFY3, a protector against autoimmunity.
Wu X, Wang Z, Croce KR, Li F, Cui J, D'Agati VD, Soni RK, Khalid S, Saleheen D, Tabas I, Yamamoto A, Zhang H. Wu X, et al. Among authors: yamamoto a. bioRxiv [Preprint]. 2024 Aug 19:2024.08.17.608411. doi: 10.1101/2024.08.17.608411. bioRxiv. 2024. PMID: 39229152 Free PMC article. Preprint.
Author's reply.
Yamamoto A, Nagao M, Sakai S, Yamaguchi J. Yamamoto A, et al. J Cardiol. 2025 Aug;86(2):221. doi: 10.1016/j.jjcc.2025.06.002. Epub 2025 Jun 16. J Cardiol. 2025. PMID: 40532852 No abstract available.
Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study.
Fukunaga A, Kakei Y, Murakami S, Kan Y, Masuda K, Jinnin M, Washio K, Amano H, Nagano T, Yamamoto A, Otsuka T, Takahagi S, Takenaka M, Ishiguro N, Hayama K, Inomata N, Nakagawa Y, Sugiyama A, Hide M. Fukunaga A, et al. Among authors: yamamoto a. Front Immunol. 2024 Sep 16;15:1441478. doi: 10.3389/fimmu.2024.1441478. eCollection 2024. Front Immunol. 2024. PMID: 39351222 Free PMC article. Clinical Trial.
Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis.
Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Hide M, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuji Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Tanese K, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Furue M, Katoh N, Nakahara T. Kido-Nakahara M, et al. Among authors: yamamoto a. J Allergy Clin Immunol Glob. 2024 Jul 31;3(4):100317. doi: 10.1016/j.jacig.2024.100317. eCollection 2024 Nov. J Allergy Clin Immunol Glob. 2024. PMID: 39253106 Free PMC article.
4,532 results